Krystal Biotech Director Sells Over $3.2 Million in Stock

Daniel Janney reduces stake in the gene therapy company by nearly 14%

Published on Mar. 5, 2026

Got story updates? Submit your updates here. ›

Krystal Biotech, Inc. (NASDAQ:KRYS) Director Daniel Janney sold 11,803 shares of the company's stock on February 27th, 2026 for a total value of $3,252,788.77. The sale represented a 13.87% decrease in Janney's ownership stake in the clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases.

Why it matters

Insider transactions, especially large sales by directors, can provide insights into a company's outlook and performance. Janney's sale of over $3.2 million in Krystal Biotech shares may signal his confidence in the company's future or a desire to diversify his personal portfolio.

The details

Janney sold the 11,803 shares at an average price of $275.59 per share. Following the transaction, he still owns 73,293 shares in the company, valued at approximately $20.2 million. Krystal Biotech's stock price has seen significant growth over the past year, rising from a 52-week low of $122.80 to a high of $298.30.

  • The share sale took place on February 27, 2026.

The players

Daniel Janney

A director at Krystal Biotech, Inc., a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases.

Krystal Biotech, Inc.

A clinical-stage biotechnology company headquartered in Pittsburgh, Pennsylvania that is focused on developing gene therapies for rare dermatological diseases.

Got photos? Submit your photos here. ›

The takeaway

Janney's sale of over $3.2 million in Krystal Biotech shares, representing a nearly 14% reduction in his ownership stake, could signal his confidence in the company's future or a desire to diversify his personal portfolio. However, without any direct commentary from Janney or the company, it's difficult to draw definitive conclusions about the motivation behind the transaction.